Literature DB >> 11171898

Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy.

J Mathieu1, H Boivin, D Meunier, M Gaudreault, P Bégin.   

Abstract

OBJECTIVE: To document the intra/interrater reliability and the construct validity of the Muscular Impairment Rating Scale (MIRS) in assessing patients with myotonic dystrophy type 1 (DM1). The MIRS is a ordinal five-point rating scale, established in accordance with the clinically recognized distal to proximal progression of the muscular involvement in DM1, based partly on a manual muscle testing (MMT) of 11 muscle groups.
METHODS: To assess the reliability of the MIRS, 55 patients with DM1 were examined by three different observers, one of them evaluating each patient twice. Intra- and interobserver reliability of the MIRS was measured using Cohen's weighted kappa. To assess the construct validity of the MIRS, correlations were made with the Functional Status Index (FSI) and eight timed functional tasks.
RESULTS: The intraobserver reliability of the MIRS was excellent (weighted kappa = 0.84), and the interobserver reliability was interpreted as a substantial agreement (weighted kappa = 0.77 to 0.79). The correlation coefficients between MMT scores and MIRS grades were all highly significant (r(s) = -0.81 to -0.88, p < 0.001). The FSI showed a significant progressive increase of the total median dependence score in activities of daily living from 0 in MIRS grade 1 to 39 in MIRS grade 5 (p < 0.001). The time needed to perform the eight functional tasks was also found to significantly increase in relation with the progression of the MIRS grades.
CONCLUSION: The MIRS is a quick, simple, and reliable measurement of muscular impairment in DM1. The FSI questionnaire and the timed motor activities supported its construct validity. The MIRS is useful to monitor major stages of DM1 progression, to study the natural history of the disease, and to identify homogeneous groups of patients for clinical trials.

Entities:  

Mesh:

Year:  2001        PMID: 11171898     DOI: 10.1212/wnl.56.3.336

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  105 in total

1.  MRI in the assessment of muscular pathology: a comparison between limb-girdle muscular dystrophies, hyaline body myopathies and myotonic dystrophies.

Authors:  R Stramare; V Beltrame; R Dal Borgo; L Gallimberti; A C Frigo; E Pegoraro; C Angelini; L Rubaltelli; G P Feltrin
Journal:  Radiol Med       Date:  2010-02-22       Impact factor: 3.469

2.  Erectile dysfunction in myotonic dystrophy type 1 (DM1).

Authors:  Giovanni Antonini; Alessandro Clemenzi; Elisabetta Bucci; Stefania Morino; Matteo Garibaldi; Micaela Sepe-Monti; Franco Giubilei; Giuseppe Novelli
Journal:  J Neurol       Date:  2009-04-27       Impact factor: 4.849

3.  Myotonic dystrophy health index: Correlations with clinical tests and patient function.

Authors:  Chad Heatwole; Rita Bode; Nicholas E Johnson; Jeanne Dekdebrun; Nuran Dilek; Katy Eichinger; James E Hilbert; Eric Logigian; Elizabeth Luebbe; William Martens; Michael P Mcdermott; Shree Pandya; Araya Puwanant; Nan Rothrock; Charles Thornton; Barbara G Vickrey; David Victorson; Richard T Moxley
Journal:  Muscle Nerve       Date:  2015-12-29       Impact factor: 3.217

4.  Brain MRI abnormalities in the adult form of myotonic dystrophy type 1: A longitudinal case series study.

Authors:  Renata Conforti; Mario de Cristofaro; Adriana Cristofano; Barbara Brogna; Angela Sardaro; Gioacchino Tedeschi; Sossio Cirillo; Alfonso Di Costanzo
Journal:  Neuroradiol J       Date:  2016-01-11

5.  Myotonic dystrophy type I combined with X-linked dominant Charcot-Marie-Tooth neuropathy.

Authors:  Hyun Sook Kim; Ki Wha Chung; Sung Hee Kang; Sung Kyung Choi; Sun Young Cho; Heasoo Koo; Sang-Beom Kim; Byung-Ok Choi
Journal:  Neurogenetics       Date:  2010-05-05       Impact factor: 2.660

6.  Increased EEG Theta Spectral Power in Sleep in Myotonic Dystrophy Type 1.

Authors:  Joseph Cheung; Chad Ruoff; Hyatt Moore; Katharine A Hagerman; Jennifer Perez; Sarada Sakamuri; Simon C Warby; Emmanuel Mignot; John Day; Jacinda Sampson
Journal:  J Clin Sleep Med       Date:  2018-02-15       Impact factor: 4.062

7.  Heart rate variability declines with increasing age and CTG repeat length in patients with myotonic dystrophy type 1.

Authors:  Bradley A Hardin; Miriam R Lowe; Deepak Bhakta; William J Groh
Journal:  Ann Noninvasive Electrocardiol       Date:  2003-07       Impact factor: 1.468

8.  Usefulness of clinical and electrocardiographic data for predicting adverse cardiac events in patients with myotonic dystrophy.

Authors:  Robert Breton; Jean Mathieu
Journal:  Can J Cardiol       Date:  2009-02       Impact factor: 5.223

9.  The use of muscle strength assessed with handheld dynamometers as a non-invasive biological marker in myotonic dystrophy type 1 patients: a multicenter study.

Authors:  Luc J Hébert; Jean-François Remec; Joanne Saulnier; Christophe Vial; Jack Puymirat
Journal:  BMC Musculoskelet Disord       Date:  2010-04-18       Impact factor: 2.362

10.  Depression in Myotonic Dystrophy type 1: clinical and neuronal correlates.

Authors:  Stefan Winblad; Christer Jensen; Jan-Eric Månsson; Lena Samuelsson; Christopher Lindberg
Journal:  Behav Brain Funct       Date:  2010-05-19       Impact factor: 3.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.